Research Analysts Set Expectations for AUTL FY2024 Earnings

Autolus Therapeutics plc (NASDAQ:AUTL - Free Report) - Research analysts at William Blair decreased their FY2024 earnings per share estimates for shares of Autolus Therapeutics in a research report issued on Tuesday, November 12th. William Blair analyst M. Phipps now expects that the company will earn ($1.09) per share for the year, down from their previous estimate of ($0.92). The consensus estimate for Autolus Therapeutics' current full-year earnings is ($0.84) per share. William Blair also issued estimates for Autolus Therapeutics' Q4 2024 earnings at ($0.33) EPS, Q1 2025 earnings at ($0.24) EPS, Q2 2025 earnings at ($0.25) EPS, Q4 2025 earnings at ($0.20) EPS, FY2026 earnings at ($0.76) EPS and FY2027 earnings at ($0.53) EPS.

A number of other brokerages have also commented on AUTL. Needham & Company LLC reaffirmed a "buy" rating and issued a $9.00 target price on shares of Autolus Therapeutics in a research report on Monday. Redburn Atlantic upgraded Autolus Therapeutics from a "neutral" rating to a "buy" rating and set a $13.00 target price on the stock in a research note on Friday. One equities research analyst has rated the stock with a hold rating and four have given a buy rating to the company's stock. Based on data from MarketBeat.com, Autolus Therapeutics currently has a consensus rating of "Moderate Buy" and a consensus target price of $9.45.

Autolus Therapeutics Stock Performance

Shares of NASDAQ:AUTL traded up $0.07 during midday trading on Friday, reaching $3.08. The company's stock had a trading volume of 2,713,999 shares, compared to its average volume of 1,442,195. The firm has a market capitalization of $819.56 million, a price-to-earnings ratio of -2.55 and a beta of 2.04. Autolus Therapeutics has a fifty-two week low of $2.94 and a fifty-two week high of $7.45. The firm has a 50 day moving average price of $3.91 and a two-hundred day moving average price of $3.98.

Autolus Therapeutics (NASDAQ:AUTL - Get Free Report) last posted its earnings results on Tuesday, November 12th. The company reported ($0.31) earnings per share for the quarter, missing analysts' consensus estimates of ($0.21) by ($0.10). During the same period in the prior year, the business earned ($0.26) earnings per share.

Institutional Investors Weigh In On Autolus Therapeutics

A number of large investors have recently added to or reduced their stakes in the company. BNP Paribas Financial Markets increased its stake in shares of Autolus Therapeutics by 2,603.8% during the first quarter. BNP Paribas Financial Markets now owns 115,399 shares of the company's stock valued at $736,000 after buying an additional 111,131 shares during the period. SG Americas Securities LLC bought a new stake in shares of Autolus Therapeutics during the 1st quarter valued at about $127,000. EntryPoint Capital LLC increased its position in shares of Autolus Therapeutics by 113.6% during the first quarter. EntryPoint Capital LLC now owns 21,540 shares of the company's stock valued at $137,000 after buying an additional 11,456 shares during the period. Affinity Asset Advisors LLC raised its stake in Autolus Therapeutics by 117.7% in the first quarter. Affinity Asset Advisors LLC now owns 3,375,000 shares of the company's stock worth $21,532,000 after buying an additional 1,824,592 shares in the last quarter. Finally, Avoro Capital Advisors LLC bought a new stake in Autolus Therapeutics during the 1st quarter valued at approximately $78,765,000. Institutional investors own 72.83% of the company's stock.

About Autolus Therapeutics

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma.